SOLV Energy's shares rose 20% in its New York debut on Wednesday, giving the solar and battery storage firm a valuation of $5.98 billion, underscoring a strong rebound in IPO activity in 2026.
George Hershman, SOLV Energy CEO, joins 'Squawk Box' to discuss the company's IPO debut, state of the solar energy market, company growth outlook, and more.
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”), a leading provider of infrastructure services to the power industry, today announced the pricing of its initial public offering of 20,500,000 shares of its Class A common stock, at a public offering price of $25.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 3,075,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions.
ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close.
Solar and battery storage firm SOLV Energy said on Friday it is targeting a valuation of up to $4.99 billion in its initial public offering in the United States.
Anchor Capital Advisors LLC reduced its position in shares of Solventum Corporation (NYSE: SOLV) by 2.2% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 597,911 shares of the company's stock after selling 13,376 shares during the period.
Solventum Corporation (NYSE: SOLV - Get Free Report) has received an average recommendation of "Hold" from the fourteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company.
Summary Marquette Asset Management, LLC initiated a new position in Solventum Corp(SOLV), purchasing 8 shares valued at approximately $630 as of its la
Solventum (NYSE: SOLV - Get Free Report) and Zicix (OTCMKTS:ZICXD - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations. Earnings and Valuation This table compares Solventum and Zicix"s revenue,
Here is how Solventum (SOLV) and Cronos Group (CRON) have performed compared to their sector so far this year.
Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn.
New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™ Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology ST. PAUL, Minn.
ST. PAUL, Minn. , Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC), the highest recognition for supply chain strength in healthcare.
Solventum offers an interesting risk/reward profile, with improving margins, disciplined reinvestment, and potential revenue growth acceleration offsetting modest core revenue growth concerns. The $725M+ Acera Surgical acquisition provides entry into a double-digit growth wound care market, though it introduces operating and sentiment risks. SOLV's 'Transform for the Future' initiative targets $500M annual cost savings, aiming to boost operating margins above 23% by 2028.
New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing.
Advisors Asset Management Inc. cut its holdings in Solventum Corporation (NYSE: SOLV) by 72.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,290 shares of the company's stock after selling 16,351 shares during the quarter. Advisors Asset Management Inc.'s holdings
Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Pre-Market Stock Futures: The futures are trading higher this morning. Sellers regained the upper hand on Monday, starting the final trading month of 2025 on the downside after a blazing Thanksgiving-week rally. All of the major indices finished the day lower, and once again, cryptocurrencies were hammered. Numerous reasons for the selling on Monday, not... Here Are Tuesday's Top Wall Street Analyst Research Calls: Albemarle, Circle Internet, Cloudflare, Danaher, Inspire Medical, Six Flags, Workday and More.
Three stocks that are performing well in 2025 just made notable buyback announcements. All three have achieved returns north of 20% this year, beating the 18% return of the S&P 500 Index.